Oklo's Small Modular Reactor Achieves Criticality, Stock Up 4.3% Premarket
0xBroomberg
Oklo's test reactor in Texas achieved a self-sustaining nuclear chain reaction, lifting shares 4.3% pre-market to $44.86 — the fifth small reactor to reach criticality under a DOE pilot, though the road from criticality to commercial operation remains long.
What does "criticality" actually mean?
Criticality — the point where a nuclear chain reaction sustains itself without external input — is the first key milestone in reactor development. The reactor can now release energy steadily.
This means → Oklo has proven the physics work. But "can it ignite?" and "can it sell electricity?" are separated by a full stack of regulatory approvals and commercialization steps.
In plain terms = the engine just turned over for the first time. Getting a license to carry passengers is a different story.
Where does the U.S. small-reactor race stand?
Oklo is the fifth company to reach criticality under the DOE's accelerated small-reactor pilot. The four before it: Aalo Atomics, Deployable Energy, Antares Nuclear, and Valar Atomics.
This reflects a loosening of regulatory barriers — feasibility validation for new nuclear tech is clearly speeding up.
The hard fact: no small modular reactor (SMR) in the U.S. is commercially operational yet. The sector is still stuck behind multiple regulatory and commercial hurdles.
How big is the Trump administration's nuclear push?
Trump signed an executive order last year requiring 10 large conventional reactors to break ground by 2030, with a long-term target of expanding national nuclear capacity to 400 GW.
The White House frames nuclear as critical infrastructure for data-center power demand and economic growth — the AI compute boom is forcing the electricity gap onto the table.
This means → policy tailwinds favor the nuclear sector broadly, but whether small reactors can catch this window depends on commercial grid-connection hitting schedule.
Shares rose 4.3% — what is the market pricing in?
Oklo gained 4.3% pre-market to $44.86. For a company with no commercial revenue, the market is trading a "technology validation" signal, not earnings.
In plain terms = investors are buying "this path works," not "this company is making money."
The real proof points lie ahead: from criticality to a commercial operating license to actual grid-tied power sales, each step can stall. Timeline uncertainty is the biggest risk.
Content is for reference only, not financial advice.